technetium-99m BRU 59-21

Technetium-99m BRU 59-21 is a **radiopharmaceutical imaging agent** consisting of technetium-99m labeled BRU 59-21, a 2-nitro-imidazole derivative designed for the **identification and imaging of hypoxic tissue** in tumors[1][3]. After intravenous administration, it accumulates selectively in hypoxic tumor cells, enabling non-invasive detection of tumor hypoxia by gamma camera or SPECT imaging. The mechanism involves retention of the 2-nitro-imidazole compound in cells under low-oxygen conditions, correlated with tissue staining for hypoxia markers such as pimonidazole[1][3]. It was primarily developed for research and diagnostic use in **head and neck cancer** patients, with preclinical studies demonstrating selective retention in hypoxic cells and safety/feasibility in humans[1].

Brand names

technetium-99m BRU 59-21technetium99m BRU 59-21technetium 99m BRU 59-21

Other names

99mTc-BRU 59-21BRU59-21BRU-59-21BRU 59-21